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Background and Rationale:  Late preterm (LPT) infants are at an increased risk for 
hyperbilirubinemia.  At a local hospital, the protocol required LPT bilirubin levels drawn at 24 
hours of life (HOL).  Stakeholders reported rarely treating LPT infants at 24 HOL.  Rather, pre-
discharge bilirubin levels (at ~ 48 HOL) would indicate treatment, often leading to increased 
length of stay (LOS).   
Purpose:  The purpose of this quality improvement initiative was to more accurately 
identify hyperbilirubinemia in LPT infants.  A new protocol was developed and implemented, 
ordering TSBs drawn at 36 HOL based on the evidence that a natural rise in bilirubin begins 
after 24 HOL.  This project evaluated the effectiveness of that initiative.    
Methodology:  Evaluation of the protocol via retrospective electronic medical records 
review, divided into three cohorts.  Data were analyzed using descriptive statistics and chi-square 
for dichotomous data.  
Outcome Measures:  Staff compliance, hospital LOS, phototherapy rates, readmissions 
for hyperbilirubinemia, and blood draw rates.   
Results:  Statistically significant improvement in compliance when comparing Cohort A 
to B (p = 0.05), Cohort A to C (p = 0.05), and Cohort A to B plus C (p < 0.001).  No statistically 
significant improvement when comparing Cohort B to C (p = 0.43).  No statistically significant 
improvement in hospital LOS among any of the cohorts.  There was no increased LOS among 
the cohorts.  Readmissions were down to zero in Cohort C.  More infants were identified and 
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treated with phototherapy as evidenced by an increase from 17.7 percent in Cohort A to 29.7 
percent and 34.9 percent in Cohorts B and C.  Blood draw rates declined steadily, down from 1.9 
per infant in Cohort A to 1.3 per infant in Cohort C.     
Conclusions:  Staff compliance was relatively low in Cohorts B and C, making it difficult 
to determine the full effects of the policy change on LOS.  As a result of the protocol change, 
more infants were identified and treated without increased LOS.  Hospital readmission rates 
dropped to zero and blood draw rates decreased across cohorts.  Improved staff compliance may 
yield greater effects of the protocol change.   
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To my husband and sons:  you have my whole heart.   
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CHAPTER 1:  INTRODUCTION 
Hyperbilirubinemia is a common neonatal condition, occurring in approximately 80 
percent of newborn infants (Bhutani, Vilms, & Hamerman-Johnson, 2010).  There are several 
physiological reasons for jaundice in newborns.  Bilirubin is a byproduct of red blood cells, 
which are produced at an increased rate and have a decreased lifespan in the newborn period 
(Hillman, 2007).  Late preterm (LPT) infants are less able to rid themselves of excess bilirubin 
because of their immature gastrointestinal tracts, hepatic systems, and immature feeding abilities, 
all of which lead to increased risk for hyperbilirubinemia (Hillman, 2007).  Because of these 
mechanisms, bilirubin tends to rise, peak, and decline by the end of the first week of life 
(Bhutani et al., 2010).  
Significance to Healthcare 
It is important to monitor and treat significant hyperbilirubinemia because in some, 
bilirubin levels would otherwise continue to rise and lead to pathological bilirubin neurotoxicity 
(Bhutani et al., 2010).  Accurate and timely postnatal screening of LPT infants can prevent acute 
bilirubin encephalopathy (ABE) which causes changes in behavioral status, muscle tone, 
lethargy, and poor feeding (Bhutani et al., 2010).  Infants who have survived ABE may be 
diagnosed with kernicterus, which is irreversible; those affected may present with such disorders 
as cerebral palsy, paralysis of upward gaze, and/or sensorineural hearing loss (Bhutani et al., 
2010).  It has been reported that early identification may predict severe hyperbilirubinemia, 
allowing for direct evidence-based interventions (Bhutani et al., 2010).   
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Local Problem 
Late preterm infants, defined as infants born at 340/7 to 366/7 weeks of gestational age 
(WGA), admitted to the University of North Carolina (UNC) Newborn Nursery (NBN), are at an 
increased risk for hyperbilirubinemia.  The NBN protocol, based on American Academy of 
Pediatrics (AAP) guidelines (Subcommittee on Hyperbilirubinemia, 2004), required total serum 
bilirubin (TSB) levels drawn at approximately 24 hours of life (HOL), in conjunction with their 
newborn metabolic screening panels.  One of the health care providers in this setting reported 
that LPT infants are rarely treated at 24 HOL (J. Haushalter, personal communication, September 
15, 2017).  Furthermore, the next bilirubin was screened at around 48 HOL, in conjunction with 
their hospital discharge, depending on the mode of delivery.  At this time the infant’s bilirubin 
level may have been high enough to warrant phototherapy, thereby delaying discharge and 
requiring longer hospitalization and/or discharge with a bilirubin blanket for home phototherapy.   
Purpose 
The purpose of this quality improvement initiative is to more accurately identify 
hyperbilirubinemia in LPT infants, by changing serum bilirubin evaluation from 24 HOL to 36 
HOL potentially treating infants sooner and decreasing their hospital length of stay (LOS).  This 
project evaluated the effectiveness of that initiative. 
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CHAPTER 2:  REVIEW OF THE LITERATURE 
Description of Search 
The specificity of this topic yielded few articles for review.  As such, there were several 
searches performed in both PubMed and the Cumulative Index to Nursing and Allied Health 
Literature (CINAHL), which were set without limitations to extract as many results as possible.  
A total of 111 articles resulted, of which, 106 were excluded, leaving five articles for review.  
Keywords used in the search strategy are found in the search results tables (Tables 1 and 2).  
Inclusion criteria were published articles that were written in English and focused on 
transcutaneous bilirubin (TcB) or TSB nomograms for infants greater than 340/7 WGA, clinical 
practice guidelines (CPGs), and expert opinion on hyperbilirubinemia.  Nomogram studies were 
excluded when the data was exclusive for infants of Asian, African, or Indian descent, which are 
not as generalizable to the local newborn nursery population. Additionally, the original 
nomogram study by Bhutani et al. (1999) was included in this report, as it is used in the AAP 
(2004) CPG for the management of hyperbilirubinemia in infants greater than 35 WGA, for a 
total of six reviewed reports.  Most studies were excluded because they sought to compare TcB 
values to TSB values and advocate for or oppose the accuracy of one method over another.     
The following tables display the search results from PubMed and CINAHL. 
Table 1: PUBMED Query 
 PubMed  
Search # Query Results 
#1 late preterm infant* AND bilirubin AND (screen OR screening*) 28 
#2 total serum bilirubin AND (late preterm infant*) 49 
#3 Transcutaneous Bilirubin Levels in Late Preterm Neonates 16 
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Table 2: CINAHL Query 
 CINAHL  
Search # Query Results 
#1 late preterm infant* AND bilirubin AND screening* 5 
#2 total serum bilirubin AND (late preterm infant*) 10 
#3 Transcutaneous Bilirubin Levels in Late Preterm Neonate* 3 
 
Study and Sample Characteristics  
Of the six articles reviewed, three were prospective cohort studies (Bhutani et al., 1999; 
Fouzas, Karatza, Skylogianni, Mantagou, & Varvarigou, 2010; Romagnoli et al., 2012), one 
CPG by the AAP (Subcommittee on Hyperbilirubinemia, 2004), and two expert opinion articles 
(Bhutani et al., 2010; Maisels et al., 2009).  The research studies sought to develop nomograms 
of bilirubin levels based on gestational age and HOL of the studied infants.  The population of 
each of the three prospective cohort studies were total population samples of live births of infants 
who met the inclusion criteria and were born at the participating hospital.  Serial bilirubin 
measurements were taken from 12 through 160 HOL, usually in 12-hour increments, and 
correlated with gestational age at birth.   
Two of the three studies produced evidence for infants born after 35 weeks gestation 
(Bhutani et al., 1999; Romagnoli et al., 2012).  The median gestational age of infants in Bhutani 
et al. was 39 WGA (1999), while 66.8 percent of infants were between 37 and 42 WGA in 
Romagnoli et al. (2012).  Only one study, Fouzas et al., produced data gathered from LPT infants 
from 340/7 to 366/7 WGA (2010).  Additionally, this nomogram was developed based on TcB 
measurements instead of serum bilirubin measurements (Romagnoli et al., 2012; Bhutani et al., 
1999).  The largest sample of infants was 2840 (Bhutani et al., 1999) then 1708 (Romagnoli et 
al., 2012), and the smallest was 793 (Fouzas et al., 2010) for a total of 5341 infants.  Each study 
provided results from a different location and country.  From Greece there were 793 infants 
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(Fouzas et al., 2010), 1708 infants from Italy (Romagnoli et al., 2012) and 2840 infants from 
Philadelphia, U. S. (Bhutani et al., 1999).  All 793 infants studied by Fouzas et al. were 
Caucasian (2010).  The racial mixture of Bhutani et al. included 43.4 percent white, 41.2 percent 
African American, with the remaining categories described as Hispanic, Asian, and other (1999).  
Infant races were not specified in the group of infants studied to produce the nomogram by 
Romagnoli et al. (2012).    
Clinical Practice Guidelines   
The AAP Subcommittee on Hyperbilirubinemia CPG (2004) recommends pre-discharge 
screening for hyperbilirubinemia.  This CPG was developed from a systematic review of 
evidence performed by the Agency for Healthcare Research and Quality (AHRQ) that examined 
the effects of high bilirubin levels on development as well as examining strategies for predicting 
significant hyperbilirubinemia (Ip et al., 2004).  Maisels et al. (2009) later clarified this 2004 
AAP guideline by further recommending screening of infants greater than 35 weeks gestation 
through use of TSB and/or TcB along with the examination of risk factors.  Risk for severe 
hyperbilirubinemia is based on where bilirubin levels plot on the risk nomogram; phototherapy 
treatment is based on where bilirubin levels plot on the treatment nomogram.  The risk 
nomogram shows bilirubin levels begin to peak sometime after 24 HOL, with sharper inclines at 
about 36 HOL before leveling off at about 96 HOL (Maisels et al., 2009). 
The expert opinion of Bhutani et al. (2010) advises a systematic approach to screening 
neonates for jaundice is needed.  Bhutani et al. (2010) also advocates for a universal bilirubin 
pre-discharge screening aimed at identifying infants in the greater than 75th percentile risk 
and/or a rate of rise (ROR) greater than 0.2 milligrams per 100 milliliters per hour (2010).    
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Age-Specific Levels of Bilirubin 
There have been two studies published since the previously discussed guidelines and 
recommendations were first made available.  Both studies developed bilirubin nomograms which 
may be used to predict future hyperbilirubinemia in late preterm infants.  Fouzas et al. (2010) 
created a TcB nomogram in LPT infants greater than 34 WGA, while the findings of Romagnoli 
et al. (2012) created a TSB nomogram on infants greater than 37 WGA and then extrapolated the 
nomogram to LPT infants greater than 35 WGA using receiver operating characteristic (ROC) 
curve analysis and statistical software to assess its predictive ability. 
Both studies demonstrate bilirubin levels that peak sometime after 24 HOL.  Romagnoli 
et al. (2012) found that the TSB nomogram indicated most infants (49 percent) reached peak 
bilirubin levels between 49 and 72 hours, and 20.5 percent peaked between 24 and 48 HOL, with 
no peaks shown before 24 HOL (2012).  Fouzas et al. (2010) found that the TcB nomogram, 
displays a natural rise in bilirubin starting at 36 HOL and peaking between 48 and 72 HOL 
(2010).   
Other than Fouzas et al. (2010), there were no studies found that examined bilirubin 
levels and nomogram data for LPT infants beginning at 34 WGA.  The Bhutani et al. (1999) 
nomogram used data from infants greater than 35 weeks gestation, and the AAP CPG (2004) 
makes its recommendation for screening on infants greater than 35 weeks gestation, missing LPT 
infants between the ages of 340/7 and 346/7 WGA.   
The nomogram cited in the CPG for the AAP guideline (2004) is based on the work of 
Bhutani et al. (1999).  The data in their work also show natural increases in bilirubin beginning 
after 24 HOL (Bhutani et al., 1999).   Like the previously discussed studies, Bhutani et al. (1999) 
data demonstrate peak levels of bilirubin closer to 48 HOL.  Each study is consistent in the HOL 
at which bilirubin levels rise and peak.  Where they differ is in bilirubin measurement type and 
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age of infants studied.  Again, the Bhutani et al. (1999) and Romagnoli et al. (2010) studies are 
both based on TSB levels while the Fouzas et al. nomograms were derived from TcB levels.  The 
age of the nomogram subjects in Bhutani et al. and Fouzas et al. were more closely aligned at 
greater than 35 WGA and greater than 34 WGA respectively.  The nomogram data for the infants 
in Romagnoli et al. (2012) findings were gathered on infants 37 to 42 WGA and then applied to 
infants greater than 35 WGA for prediction of risk for hyperbilirubinemia.   
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CHAPTER 3:  CONCEPTUAL MODEL 
Identified Theory and Its Essential Points 
 Because this is a program evaluation analyzing a change in practice, the guiding model 
for this Doctorate in Nursing Practice (DNP) project was The Model for Improvement (MFI).  
This model comes from the discipline of improvement science and was developed by an 
organization called Associates in Process Improvement (API) in 1996 as a way of demonstrating 
how to rapidly facilitate change (Courtlandt, Noonan, & Feld, 2009).  Designed to help 
organizations “accelerate improvement,” the model has two parts:  answer and/or address three 
fundamental questions and Plan-Do-Study-Act cycles (Institute for Healthcare Improvement, 
n.d.).  Plan-Do-Study-Act cycles (PDSA) are not the invention of API.  Deming, well known in 
the field of quality improvement, developed the PDSA concept from adaptations of Walter 
Shewart’s work in statistical methods (Harolds, 2015).   
Application of The Model for Improvement to Project 
The three fundamental questions proposed by the MFI are as follows:  “what are we 
trying to accomplish,” “wow will we know that a change is an improvement,” and “what change 
can we make that will result in improvement” (Associates in Process Improvement, n.d.)?   In 
order to determine “what we are trying to accomplish,” one must set aims (Courtlandt et al., 
2009).  The aims should be clearly described, to include a rationale and convey its importance, 
and also be measurable (Courtlandt et al., 2009). In this project, the main aim is to determine 
whether or not the protocol will decrease LOS in treated infants.  Staff compliance was another 
important outcome measure because it has an effect on all outcomes in the study.  There were 
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also several measurable sub-aims to consider:  decreased re-hospitalization of LPT infants, rates 
of phototherapy, and decreased blood draws.  These aims were evaluated by data collected from 
the electronic medical records (EMRs).   
The question of “how we will know that a change is an improvement” is addressed 
during the improvement process by looking at outcomes, process, and balancing measures 
(Courtlandt et al., 2009).   The “outcome” is decreased LOS.   The “process” in the case of this 
DNP project refers to the newly implemented practice change intervention, while the “balancing 
measures” are those measures which will determine if a change is causing unexpected effects 
(Courtlandt et al., 2009).  
The final question, “what changes can we make that will result in an improvement” could 
be answered by the “change package,” which is evidenced-based change that can affect a 
particular outcome (Courtlandt et al., 2009).   In the NBN project, the selected change is to test 
TSB levels at 36 HOL.  The timing of TSB testing follows the hourly ROR bilirubin nomogram 
used by Bhutani et al. (1999), which demonstrates the natural rise in bilirubin levels tends to 
peak after 24 HOL.  Bhutani et al. (1999) is used in the AAP guideline (2004) on the 
management of hyperbilirubinemia in infants greater than 35 weeks gestation. 
Part two of the model is the PDSA component.  These cycles are where the scientific 
method are put into action (Institute for Healthcare Improvement, n.d.).  Many quality 
improvement models use PDSA cycles in their methodology.  In the MFI, the first cycle of 
PDSA is a hypothesis test (Lee & Larson, 2014).  The “plan” and “do” portions of the cycle 
involve identifying the area of improvement, strategizing ways to implement the intervention, 
and collecting the baseline data (Lee & Larson, 2014).  One key source of baseline data in this 
project is the electronic medical record (EMR).  In the “study” and “act” portion of the cycle, 
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baseline data is studied and action is taken to address the root cause of the problem (Lee & 
Larson, 2014).   
Justification for Use of The Model for Improvement 
The MFI model is known for being both rigorous and reasonable for busy practitioners 
who seek to improve patient outcomes.  Evaluating the proactive change in the newborn 
nursery’s collecting TSBs of LPT infants at 36 HOL is compatible with the PDSA cycles.  The 
PDSA cycle takes a step-by-step approach, allows for making predictions, and encourages 
thoughtful consideration on the new knowledge obtained, all of which facilitates change and 
rapid adaptation (Courtlandt et al., 2009).  This method allows for small scale changes, which 
stakeholders at the site stated was more manageable for their nursing staff.  Using MFI as the 
guiding model for this intervention will meet the needs of the nursery staff who are charged with 
performing the intervention.  Evaluating the implementation of a small scale change following 
the guidance of a model like MFI may encourage buy-in from the staff and stakeholders, which 
is crucial to any quality improvement project.  
Using a model grounded in theory, like MFI, also helps define the project in a scholarly 
manner.  Just as the American Association of Colleges of Nurses outlined in the DNP Essentials 
(2006), use of science-based theories and concepts applied to the newborn nursery project will 
help determine healthcare delivery and evaluate the outcomes of the proposed intervention.  
Without the use of MFI, this project would not have a systematic approach to testing the 
proposed intervention or reviewing the pre and post data to make a determination as to whether 
or not the intervention successfully met its aims.  For example, the team could suspect that 
testing TSBs at 36 HOL would lead to earlier and more accurate identification of 
hyperbilirubinemia in LPT infants, however, without collecting the data and analyzing the 
results, this would remain a “hunch” without any scientific measurements to verify the claim.  
11 
CHAPTER 4:  DNP PROJECT PLAN 
Setting and Key Personnel  
This project was implemented in the NBN at UNC Hospital (UNCH).  There were 3433 
births in 2017 according to the most recent “UNC Women’s Hospital Monthly Delivery Report” 
(2018).  One-third of the infants eligible for NBN care are either LPT or at risk for 
hypoglycemia, as defined by hypoglycemia protocol inclusion:  large for gestational age (LGA), 
small for gestational age (SGA), infant of diabetic mother (IDM) or LPT (J. Haushalter, personal 
communication, February 7, 2018).  The project lead (PL) worked closely with J. Haushalter, a 
nurse practitioner (NP) in the NBN and the liaison between the PL and the key personnel within 
the nursery.  The UNCH NBN pediatric service includes a team of NPs, pediatric physician 
residents, and attending physicians.  Key personnel for this project include the medical director, 
NPs, and physicians (local term used for all is licensed independent practitioners or LIPs), nurse 
managers, staff nurses, and medical technicians.  These personnel are responsible for 
administering the practice change, educating the staff, and implementing the new protocol. 
Design 
This project evaluated the following practice change for effectiveness and sustainability.   
The first PDSA cycle in the newborn nursery occurred as follows:  the problem of missing early 
identification of hyperbilirubinemia was identified by stakeholders in the nursery.  Based on 
external evidence the practice change agreed upon was to test serum bilirubin levels at 36 rather 
than 24 HOL.  Prior to the practice change, TSBs were drawn at 24 HOL and rarely resulted in 
phototherapy treatment (J. Haushalter, personal communication, September 15, 2017).  Because 
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bilirubin screening was not occurring at 36 HOL, and the mother and infant were in the hospital 
for at least 48 hours depending on the delivery method, the next bilirubin was screened at around 
48 HOL, at which time bilirubin levels may have been high enough for phototherapy treatment.  
As such, discharge may have been delayed for treatment, or the infant sent home with a bilirubin 
blanket.  Stakeholders hypothesized that by moving the standard TSB screening from 24 HOL to 
36 HOL, hyperbilirubinemia would be determined at 36 rather than 48 HOL (J. Haushalter, 
personal communication, February 26, 2018).  As a safety measure all infants continued to 
receive a TcB screening at 24 HOL, and if greater than 7mg/dL, a TSB was ordered by the LIP 
or RN according to the standing orders (J. Haushalter, personal communication, March 8, 2018).  
On December 17, 2017 the electronic order set and protocol were revised to reflect these 
changes.  On March 1, 2018, the start of the second PDSA cycle, two NP providers in the 
newborn nursery provided additional education on the practice change and its intent to the 
newborn nursery staff nurses. 
The PL gathered baseline data from before (Cohort A), during (Cohort B), and after the 
second PDSA cycle (Cohort C) of the practice change in order to evaluate the effectiveness of 
the protocol.  The program evaluation included analysis of the post-improvement aspect of the 
PDSA cycles, assessing effectiveness, degree of gain, and sustainability of any degree of gain 
achieved (Lee & Larson, 2014). 
Data Collection 
Data was extracted from the EMRs.  No protected health information (PHI) was 
collected.  Data was entered into an excel spreadsheet (see Appendix A).  Gestational age was 
defined as the number of weeks and days of completed gestation.  Only infants with a GA of 35 
0/7 – 36 6/7 were evaluated in this project; no infants below 35 0/7 weeks were admitted to the 
NBN during the study period.  Transcutaneous bilirubin with HOL was defined as the TcB level 
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at hour of life for the infant.  In addition, it was determined if this measurement was taken within 
the protocol guidelines and recorded as “yes” or “no”.  For example, TSB is ordered at 36 HOL 
for LPT newborns.  The window for compliance is “+” (plus) or “-“ (minus) 4 hours.  Therefore, 
if the TSB was performed at 32 – 40 HOL it was considered in compliance and “yes” was 
recorded on the data collection tool.  Infant delivery method was recorded as spontaneous 
vaginal delivery (SVD) or cesarean section (CS).  Orders for initiation of phototherapy were 
recorded as “yes” or “no.”  If there are discharge orders for continued home phototherapy this 
will also be noted as “yes” or “no.” 
 The primary outcome measure of LOS was recorded in days based on admission and 
discharge dates and times.  If there was use of a boarder room, this was to be recorded as “yes” 
or “no” and then the number of days also recorded.  
Data Analysis 
Data from the three study periods was analyzed using descriptive statistics as well as 
comparison statistics, t-tests for continuous data, and chi-square for categorical or dichotomous 
data.  To determine if the practice change lead to a reduced LOS, average LOS in infants 
diagnosed with hyperbilirubinemia and who were treated with phototherapy were compared 
before, during, and after the implementation period.  In addition, LOS beyond the expected two 
days for a vaginal birth and three days for a cesarean birth was compared.  Readmission rates 
were determined by EMR review of infants diagnosed with hyperbilirubinemia and readmitted to 
UNC pediatrics unit within seven days of discharge.  Compliance rate were determined by 
comparing time of TSB testing to the protocol window of compliance. 
The PL also carefully reviewed records for other factors that impacted LOS.  These co-
morbidities were collected to provide additional context for the cause for a LOS that exceeded   
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expectations.  Vaginal and caesarian births have different baseline hospital lengths of stay and 
were appropriately identified in the data.  Finally, no EMRs of LPT infants with pathological 
jaundice were included. 
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CHAPTER 5:  DEMOGRAPHICS 
Patient Characteristics 
A total of 200 electronic charts were reviewed, of which 37 were discarded because the 
patient was deceased, did not meet the defined inclusion criteria of being between 340 and 366 
WGA, was transferred to the Neonatal Intensive Unit, or had ABO blood type incompatibility 
with a positive direct antigen test.  The remaining 163 records were divided into three cohorts.    
Cohort A.  This was the largest group, with 73 records included for LPT infants born 
between August 1, 2017 and December 12, 2017.  Because these dates are just prior to the 
protocol implementation, this is the baseline data and the group to which all other cohorts are 
compared.  The majority of the cohort was male at 55 percent and the largest racial or ethnic 
groups were Hispanic at 35.6 percent and White at 34.2 percent.  Blacks represented the third 
largest racial group at 19.2 percent, with the rest of the patients identifying as Asian (6.8 
percent), Other (2.7 percent), or Unknown (1.4 percent).  The mean gestational age was 362.    
Just over 17 percent of infants required phototherapy.  Of these infants, four (36.4 percent) had 
co-morbidities, ranging from one to two additional diagnoses. 
Cohort B.  The second largest group with 47 included records, the infants in this cohort 
were born between December 13, 2017 and February, 28, 2018.  The NBN protocol became 
effective on December 13th, thus this time period directly follows implementation of the new 
policy and is within the early stages of its integration into practice.  Fifty five percent of LPT 
infants were male and 55 percent were also White.  Nineteen percent and 8.5 percent of infants 
were identified as Hispanic and Black, respectively.  The remaining infants were identified as 
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Other (10.6 percent) or Asian (6.4 percent).  The mean gestational age was also 362.  Nearly 30 
percent of infants required phototherapy.  Of these infants, four (28.6 percent) had co-
morbidities, ranging from one to three additional diagnoses. 
Cohort C.  There were 43 records included in this group of infants, born between  
March 1, 2018 and June 1, 2018.  During this time period, the protocol had been fully established 
and integrated into practice.  Male infants outnumbered female infants 51.2 to 48.8 percent.  
White infants represented 53.5 percent of the cohort, followed by Black infants at 20.9 percent, 
Hispanic infants at 14 percent, Asian infants at 4.7 percent, and Unknown infants at 2.3 percent.  
This group also had additional racial and ethnic categories identified.  Infants identified as 
“Black and White” and American Indian or Alaskan Native represented at 2.3 percent each.  The 
mean gestational age in this group was 361.  Nearly 33 percent of infants required phototherapy.  
Of these infants, four (26.7 percent) had co-morbidities, ranging from one to two additional 
diagnoses. 
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CHAPTER 6:  RESULTS 
Outcome Measure:  Compliance 
To measure compliance with the new protocol Cohort A was compared to Cohorts B, C, 
and B plus C; additionally, Cohort B was compared to C.  Compliance was determined as either 
“yes” or “no” based on the following criteria:  if the TSB was drawn between 32 and 40 HOL.  
There was statistically significant improvement in compliance when comparing Cohort A to B (p 
= 0.05), Cohort A to C (p = 0.05), and Cohort A to B plus C (p < 0.001).  There was no 
statistically significant improvement when comparing Cohort B to C (p = 0.43).  These findings 
indicate there was improvement from the baseline data, with a decrease in compliance between 
early implementation and established integration into practice.  In the pre-implementation phase 
(Cohort A), 17.8 percent of LPT infants had a TSB level drawn on or about 36 HOL.  There were 
63.8 percent drawn on or about 36 HOL in Cohort B, and 55.8 percent in Cohort C.   
Outcome Measure:  Hospital Length of Stay 
 One of the drivers for screening for hyperbilirubinemia at 36 HOL, was to more closely 
align with the natural rise in bilirubin levels and to potentially decrease hospital LOS by treating 
infants sooner.  Cohort A was compared to Cohorts B, C, and B plus C to measure LOS 
outcomes.  There was no statistically significant change in hospital LOS among any of the 
cohorts.  Cohort A had 20.5 percent of infants exceeding hospital LOS beyond expectations, with 
25.5 percent in Cohort B, and 23.3 percent in Cohort C.  However, there were factors other than 
hyperbilirubinemia which impacted hospital LOS for LPT infants among the three cohorts (see 
Appendix B).  After removing those cases, 5.5 percent (four infants) with hyperbilirubinemia 
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exceeded the expected LOS in Cohort A, while 6.4 percent (three infants) and 9.3 percent (four 
infants) exceeded in Cohorts B and C, respectively.   
Description of Other Outcome Measures:  Phototherapy, Hospital Readmission, and Blood 
Draw Rates 
 There were other key findings in the evaluation of this practice change worth describing.  
Rates of phototherapy increased among Cohorts B and C.  Cohort A had 17.7 percent of infants 
on phototherapy compared to nearly 30 percent of LPT infants in Cohort B and 34.9 percent in 
Cohort C received phototherapy.   
There was an overall decrease in readmission rates for hyperbilirubinemia within seven 
days of discharge.  The readmission rate for Cohort A was five percent (four infants), and nine 
percent (four infants) for Cohort B.  Cohort C had no readmissions.  A significant caveat to one 
of the readmitted patients in Cohort B was uncovered during the chart review.  This patient had a 
bilirubin blanket ordered for home use at discharge, which was not delivered by the home health 
company.  This readmission was beyond the hospital’s control; had it not occurred, the 
readmission rate for Cohort B could have been six percent.   
Blood draw rates also decreased from the beginning of the protocol evaluation.  Cohort A 
had 1.9 blood draws per infant.  Rates decreased to 1.6 and 1.3 blood draws per infant among 
Cohorts B and C.  
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CHAPTER 7:  DISCUSSION 
The primary aim of this evaluation was to determine if the practice change had the effect 
of decreasing hospital LOS.  Staff compliance was also measured, which is vital to successful 
implementation of any new protocol and has an impact on positive patient outcomes.   
Compliance.  There was statistically significant improved compliance when comparing 
all cohorts except B to C.  Compliance decreased from 63.8 percent in Cohort B to 55.8 percent 
in Cohort C.  This demonstrates a fall in compliance from the initial implementation to the 
established practice change.  Given the overall low rate of compliance and the relatively small 
number of treated newborns in the review, it is difficult to determine effectiveness of the 
protocol change to LOS.  One cannot expect to see measured changes to the protocol without 
adequate staff compliance.  There are several possible reasons for the low rates of compliance:  
staff turnover, unclear protocol guidelines, unclear understanding of protocol goals, inadequate 
or ineffective training.  Staff compliance with the practice change could have a substantial 
impact on hospital LOS.  The project results show an increase in treated infants since the 
protocol began.  More infants were identified and treated earlier without significantly increasing 
LOS, without increasing lab draws, and with fewer readmissions.  With increased compliance, 
the potential for improvement in these outcomes is significant.  
Hospital length of stay.  There was no significant change in LOS between the cohorts.  
Hospital LOS was exceeded among LPT infants receiving phototherapy in roughly the same 
numbers across cohorts, ranging from 5.5 percent (four infants) in Cohort A, 6.4 percent (three 
infants) in Cohort B, and 9.3 percent (four infants) in Cohort C.  The decrease in compliance 
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between Cohorts B and C could have implications in hospital LOS and phototherapy treatment in 
affected infants.  Given the overall low rate of compliance and the relatively small number of 
treated newborns in the review, it is difficult to fully determine effectiveness of the protocol 
change to LOS.    
 Phototherapy rates.  The two nomogram studies designed for LPT infants, Fouzas et al. 
(2010) TcB nomogram and Romagnoli et al. (2012) TSB nomogram, both depict bilirubin levels 
peaking after 24 HOL, with no peaks shown before 24 HOL.  The TSB nomogram of the 
Romagnoli et al. (2012) study, shows nearly half of their infants reaching peak bilirubin levels 
between 49 and 72 HOL, and one fifth reaching peak levels between 24 and 48 hours.  The 
protocol evaluation found that there was an increase in phototherapy treatment after 
implementation, which seems to correspond to the evidence displayed in the TSB and TcB 
nomograms.  Phototherapy treatment for Cohort A at 17.7 percent compared to 29.7 percent and 
34.9 percent in Cohorts B and C is consistent with what the evidence cited in this study shows.  
That is to say, 20 to 50 percent of infants reached peak bilirubin levels after 24 hours and before 
72 hours in data collected by Romagnoli et al. (2012).  This suggests that timing TSB for 36 
HOL is beneficial for LPT infants, potentially leading to increased treatment at the most 
appropriate time and possibly preventing readmissions for hyperbilirubinemia. 
 Hospital readmission and blood draw rates.  The overall rates of hospital readmissions 
and blood draws decreased during the study period.  These findings could be related to the 
statistically significant improvement in compliance with the new protocol.  As infants were 
screened closer to the natural rise in bilirubin levels, higher rates of infants were treated for 
hyperbilirubinemia.  This should naturally lead to decreased readmission rates, as infants 
(previously screened at 24 HOL) were being treated when TSB levels would more likely indicate 
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the need for phototherapy (i.e., 36 HOL) as opposed to going home and being diagnosed after 
discharge.  Additionally, the downward trends of blood draws, combined with increased 
phototherapy for affected patients could indicate a more timely screening of hyperbilirubinemia 
as hypothesized.  
Hispanic demographic.   The AAP guideline (2004) uses Bhutani et al. (1999) 
nomogram.  The sample in this study included a much smaller makeup of Hispanic infants than 
that of this project.  Twenty five percent of the total number of LPT infants in this study were 
Hispanic, while just 3.6 percent of infants were Hispanic in Bhutani et al. (1999).  This racial 
difference may have an unknown impact on hyperbilirubinemia recognition and treatment.   
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CHAPTER 8:  PRACTICE IMPLICATIONS AND RECOMMENDATIONS 
This evaluation identified the need for improved protocol compliance to better determine 
its effect on LOS and improved treatment timing.  Asking, “How will we know that a change is 
an improvement,” is one of the key three questions used in the guiding model for this project, 
The Model for Improvement.  The protocol evaluation reveals a decrease in compliance between 
Cohorts B and C, which is implicated in the results of the remaining outcome measures.  It is 
recommended that stakeholders review the results of the study and also take steps to ensure staff 
compliance with the new policy improves and is sustainable in the future. The previous policy 
was well established for years and it is not unexpected to have less than perfect compliance to a 
new policy or procedure. Staff education, peer-performance monitoring, ownership of the 
required change, staff champions, and performance feedback are all possible compliance 
improvement methods (Hennessy & Dynan, 2014).  It is also important to provide continuous 
feedback to staff members who are performing the practice change at regular intervals.    
Additionally, the overall number of patients included in the review was relatively small.  
The number of patients who received phototherapy or were readmitted within seven days of 
discharge were too small to perform analyses for difference beyond descriptive statistics.  Case 
series evaluations are recommended to perhaps determine more specific individual infant safety 
and quality of care improvements.   
Finally, one of the initial outcomes to be measured was the use of boarding rooms.  This 
was an important measurement to stakeholders for further tracking of hospital LOS.  
Unfortunately, there was no consistent documentation of boarding room use in the EMR.  If a 
23 
patient was admitted for longer than expected, given the method of delivery, it was assumed the 
patient’s mother was placed in a boarding room until the patient was discharged.  This could not 
be proven, except for one chart, where the mother’s use of the boarding room was documented 
narratively.  It is recommended that the use of a boarding room be added as a chart detail by 
EPIC or, at least included in the progress notes written by providers. 
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CHAPTER 9:  STRENGTHS, WEAKNESSES, AND SUSTAINABILITY 
Demonstrating that testing LPT infants for hyperbilirubinemia at 36 rather than 24 HOL 
does, in fact, more accurately identify LPT infants with hyperbilirubinemia would be the main 
strength for any program evaluation examining the timing of screening for jaundice.  This gain 
would allow for the earlier treatment of LPT infants with hyperbilirubinemia and hopefully 
reduce hospital LOS.  However, there are also drawbacks worth considering.  Poor compliance 
during the testing phase could skew the results of outcomes.  If the staff continued to draw TSBs 
at 24 hours during the testing phase, this would nullify the results of the project.  Ensuring staff 
are trained on the new protocol as well as educated about the aims and sub-aims will facilitate 
better compliance. A review of the protocol guidelines for clarity, periodic staff training, chart 
auditing, and other accountability measures are all possible ways to improve and sustain 
compliance among staff.  
Another limitation could be a lack of maintaining the change if the data demonstrated 
significant gains.  Ongoing measurement is necessary for sustaining improvement (Courtlandt et 
al., 2009).  If stakeholders view the results as significant, a simple auditing process could be set 
up, perhaps incorporated into the shift duties to ensure continuous data collection.  Again, 
frequent data collection is needed to determine if the process does or does not remain effective 
(Courtlandt et al., 2009).
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CHAPTER 10:  CONCLUSIONS 
Late preterm infants are at higher risk for developing hyperbilirubinemia because of their 
immature physiological systems.  Because of the pathological effects of bilirubin toxicity, 
accurate and timely screening and treatment is imperative.  The NBN sought to improve their 
screening process, thereby improving the timing of treatment with the 36 HOL TSB screening 
protocol.   
The results are promising.  Overall phototherapy treatment levels increased, readmission 
rates decreased, and laboratory blood draws decreased without significantly increasing hospital 
LOS.  While not designed to determine cause and effect, the results of this practice change are 
encouraging and demonstrate that despite the lower than desired compliance rate, the project 
goals were met.  
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APPENDIX A:  DATA EXTRACTION TOOL 
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MRN = medical record number TSB = total serum bilirubin LOS = length of stay
TcB = transcutaneous bilirubin Y = yes SVD = spontaneous vaginal delivery
HOL = hour of life N = no CS = cesarean section
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APPENDIX B:  OTHER FACTORS AFFECTING HOSPITAL LENGTH OF STAY 
Table 4: Other Factors Affecting Hospital Length of Stay 
Other Factors Affecting Hospital LOS   
Cohort A Cohort B Cohort C 
NAS NAS Poor feeder 
Poor feeder Poor feeder Failed car seat tests 
Hypoglycemia Failed car seat tests Excessive weight loss 
RDS Excessive weight loss Hypoglycemia 
Maternal HTN  RDS 
Renal anomalies  Renal anomalies 
Failed car seat tests  Neural tube defect 
Excessive weight loss  R/O infection 
Trisomy 21     
NAS = neonatal abstinence syndrome   
RDS = respiratory distress    
HTN = hypertension    
R/O = rule out     
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